Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company …
Over the last 12 months, insiders at Genenta Science S.p.A. have bought $0 and sold $0 worth of Genenta Science S.p.A. stock.
On average, over the past 5 years, insiders at Genenta Science S.p.A. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $18,750 was made by Sanders Walter Lloyd (VP, Sales & Marketing) on 2006‑11‑15.
2006-11-15 | VP, Sales & Marketing | 25,000 0.0197% | $0.75 | $18,750 | ||||
2006-06-23 | VP, Sales & Marketing | 56 <0.0001% | $1.63 | $91 | ||||
2006-06-15 | VP, Sales & Marketing | 577 0.0009% | $1.51 | $874 | ||||
2006-05-12 | director | 15,000 0.023% | $1.46 | $21,900 | ||||
2004-05-05 | Sale | 10 percent owner | 940,000 4.8924% | $4.95 | $4.65M | |||
2004-05-04 | Sale | 10 percent owner | 6.31M 32.6423% | $4.92 | $31.05M | |||
2004-05-03 | Sale | 10 percent owner | 2.75M 14.6019% | $5.05 | $13.89M | |||
2004-03-23 | 10 percent owner | 5,000 0.0495% | $9.42 | $47,100 | ||||
2004-03-16 | 10 percent owner | 5,000 0.0541% | $10.29 | $51,450 | ||||
2003-10-20 | 10 percent owner | 5,000 0.0529% | $10.07 | $50,350 | ||||
2003-09-10 | 10 percent owner | 5,000 0.0824% | $15.68 | $78,400 |